Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Abstract Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction therapy followed by reduced-dose etanerc...

Full description

Bibliographic Details
Main Authors: Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones, Lisa Marshall
Format: Article
Language:English
Published: BMC 2018-01-01
Series:Arthritis Research & Therapy
Subjects:
Rheumatoid arthritis
Treatment
Remission
Low disease activity
Etanercept
Methotrexate
Online Access:http://link.springer.com/article/10.1186/s13075-017-1484-9

Internet

http://link.springer.com/article/10.1186/s13075-017-1484-9

Similar Items